Avaliação do uso de células tronco no tratamento de lesões medulares espinhais.
DOI:
https://doi.org/10.36557/2674-8169.2026v8n3p1109-1124Palavras-chave:
Células tronco, lesão medular, medula espinhal, fraturas espinhais, degerenação da medula espinhal, tratamento com células troncoResumo
As lesões medulares espinhais são um grande problema da medicina moderna tanto pelo seu caráter crônico e permanente, quanto pela grande gama de complicações que ela traz para a vida do paciente. Atualmente, é possível ter uma esperança de uma terapia que consiga trazer para tal paciente uma melhora significativa da qualidade de vida, e que traga também uma melhora da função motora e sensitiva, e essa esperança é a célula tronco. O objetivo dessa revisão integrativa avaliar a segurança, viabilidade e eficácia do tratamento do uso de células tronco em lesões de medula espinhal. Foi realizada um busca prévia nas plataformas PubMed e BVS, utilizando os descritores ‘’stem cells’’ e ‘’ spinal injury’’ utilizando o operador booleano “AND”, tendo um total de 24 artigos que foram selecionados após a aplicação de critérios de inclusão, sendo eles - artigos publicados nos últimos 5 anos (2019-2024), artigos cujo estudos eram ensaios clínicos, ensaios clínicos controlados e estudos observacionais; e os de exclusão são - artigos fora do tema, e artigos que não foram possíveis de serem lidos na íntegra. De acordo com os estudos selecionados, a terapia com células tronco possui uma boa segurança, uma boa viabilidade, e uma boa eficácia que ainda necessita de melhores conclusões. Em conclusão, é possível dizer que a terapia com células tronco é um tratamento viável para lesões de medula espinhal, e que representa grande melhora, tanto motora e sensitiva, quanto para a qualidade de vida do paciente. Porém, ainda é de suma importância que as células tronco continuem sendo estudadas, e que maiores ensaios clínicos sejam feitos no futuro, com o objetivo de se chegar conclusões mais definitivas.
Downloads
Referências
Karsy M, Hawryluk G. Modern Medical Management of Spinal Cord Injury. Curr Neurol Neurosci Rep. 2019 Jul 30;19(9):65-71.
Zakrzewski W, Dobrzyński M, Szymonowicz M, Rybak Z. Stem cells: past, present, and future. Stem Cell Res Ther. 2019 Feb 26;10(1):68-89.
Bydon M, Qu W, Moinuddin FM, Hunt CL, Garlanger KL, Reeves RK, et al. Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial. Nat Commun. 2024 Apr 1;15(1):2201-11. Erratum in: Nat Commun. 2024 Jun 5;15(1):4799-801.
Zamani H, Soufizomorrod M, Oraee-Yazdani S, Naviafar D, Akhlaghpasand M, Seddighi A, et al. Safety and feasibility of autologous olfactory ensheathing cell and bone marrow mesenchymal stem cell co-transplantation in chronic human spinal cord injury: a clinical trial. Spinal Cord. 2021 Sep 9;59(9):917-26
Honmou O, Yamashita T, Morita T, Oshigiri T, Hirota R, Iyama S, et al. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clinical Neurology and Neurosurgery. 2021 Apr;203:106565.
Shim J, Kim KT, Kim KG, Choi UY, Kyung JW, Sohn S, et al. Safety and efficacy of Wharton’s jelly-derived mesenchymal stem cells with teriparatide for osteoporotic vertebral fractures: A phase I/IIa study. Stem Cells Translational Medicine [Internet]. 2020 Dec 16;10(4):554–67.
Fessler RG, Ehsanian R, Liu CY, Steinberg GK, Jones L, Lebkowski JS, et al. A phase 1/2a dose-escalation study of oligodendrocyte progenitor cells in individuals with subacute cervical spinal cord injury. Journal of Neurosurgery: Spine. 2022 Jul 1;1–9.
Koda M, Imagama S, Nakashima H, Ito S, Segi N, Ouchida J, et al. Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial. Stem Cell Res Ther. 2024 Aug 13;15(1):259-67.
Albu S, Kumru H, Coll R, Vives J, Vallés M, Benito-Penalva J, et al. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021 Feb;23(2):146–56.
Levi AD, Anderson KD, Okonkwo DO, Park P, Bryce TN, Kurpad SN, et al. Clinical Outcomes from a Multi-Center Study of Human Neural Stem Cell Transplantation in Chronic Cervical Spinal Cord Injury. Journal of Neurotrauma. 2019 Mar 19;36(6):891–902.
Awidi A, Al Shudifat A, El Adwan N, Alqudah M, Jamali F, Nazer F, et al. Safety and potential efficacy of expanded mesenchymal stromal cells of bone marrow and umbilical cord origins in patients with chronic spinal cord injuries: a phase I/II study. Cytotherapy. 2024 Aug;26(8):825-831.
12.
Curt A, Hsieh J, Schubert M, Hupp M, Friedl S, Freund P, et al. The Damaged Spinal Cord Is a Suitable Target for Stem Cell Transplantation. Neurorehabilitation and Neural Repair. 2020 Jul 23;34(8):758–68.
Akhlaghpasand M, Tavanaei R, Hosseinpoor M, Yazdani KO, Soleimani A, Zoshk MY, et al. Safety and potential effects of intrathecal injection of allogeneic human umbilical cord mesenchymal stem cell-derived exosomes in complete subacute spinal cord injury: a first-in-human, single-arm, open-label, phase I clinical trial. Stem Cell Res Ther. 2024 Aug 26;15(1):264-76.
Faleiros F, de Oliveira Braga DC, Schoeller SD, Henriques SH, Cunha NBF, Videira LGN, et al. Surveying people with spinal cord injuries in Brazil to ascertain research priorities. Sci Rep. 2023 Jan 12;13(1):654-61.
Saini R, Pahwa B, Agrawal D, Singh P, Gurjar H, Mishra S, et al. Safety and feasibility of intramedullary injected bone marrow–derived mesenchymal stem cells in acute complete spinal cord injury: phase 1 trial. Journal of Neurosurgery: Spine [Internet]. 2022 Apr 8 [cited 2023 May 7];37(3):331–8.
Dettori JR, Skelly AC, Brodt ED. Spine Treatment Appraisal Report (STAR): Bone Marrow-Derived Stem Cells Improve Neurological Recovery in Participants With Spinal Cord Injury. Global Spine Journal. 2020 Nov 20;11(1):122–3.
Yang Y, Pang M, Du C, Liu ZY, Chen ZH, Wang NX, et al. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study. Cytotherapy [Internet]. 2021 Jan 1 [cited 2021 Oct 29];23(1):57–64.
Deng WS, Ma K, Liang B, Liu XY, Xu HY, Zhang J, et al. Collagen scaffold combined with human umbilical cord-mesenchymal stem cells transplantation for acute complete spinal cord injury. Neural Regen Res. 2020 Sep;15(9):1686-700.
Yang Y, Pang M, Chen YY, Zhang LM, Liu H, Tan J, et al. Human umbilical cord mesenchymal stem cells to treat spinal cord injury in the early chronic phase: study protocol for a prospective, multicenter, randomized, placebo-controlled, single-blinded clinical trial. Neural Regen Res. 2020 Aug;15(8):1532-38.
Chen YT, Tsai MJ, Hsieh N, Lo MJ, Lee MJ, Cheng H, et al. The superiority of conditioned medium derived from rapidly expanded mesenchymal stem cells for neural repair. Stem Cell Res Ther. 2019 Dec 16;10(1):390.
Srivastava R, Agrahari A, Singh A, Chandra T, Raj S. Effectiveness of bone marrow-derived mononuclear stem cells for neurological recovery in participants with spinal cord injury: A randomized controlled trial. Asian Journal of Transfusion Science. 2019;13(2):120-8.
Jones JM, DePaul MA, Gregory CR, Lang BT, Xie H, Zhu M, et al. Multipotent Adult Progenitor Cells, but Not Tissue Inhibitor of Matrix Metalloproteinase-3, Increase Tissue Sparing and Reduce Urological Complications following Spinal Cord Injury. Journal of Neurotrauma. 2019 May 1;36(9):1416–27.
Nakazaki M, Lankford KL, Yamamoto H, Mae Y, Kocsis JD. Human mesenchymal stem-derived extracellular vesicles improve body growth and motor function following severe spinal cord injury in rat. Clin Transl Med. 2023 Jun;13(6):e1284.
Orlandin JR, Gomes IDS, Sallum Leandro SF, Fuertes Cagnim A, Casals JB, Carregaro AB, et al. Treatment of Chronic Spinal Cord Injury in Dogs Using Amniotic Membrane-Derived Stem Cells: Preliminary Results. Stem Cells Cloning. 2021 Oct 18;14:39-49.
Yoo SH, Lee SH, Lee S, Park JH, Lee S, Jin H, et al. The effect of human mesenchymal stem cell injection on pain behavior in chronic post-ischemia pain mice. The Korean Journal of Pain. 2020 Jan 1;33(1):23–9.
Huang JH, Xu Y, Yin XM, Lin FY. Exosomes Derived from miR-126-modified MSCs Promote Angiogenesis and Neurogenesis and Attenuate Apoptosis after Spinal Cord Injury in Rats. Neuroscience. 2020 Jan;424:133–45.
Roberts TT, Leonard GR, Cepela DJ. Classifications In Brief: American Spinal Injury Association (ASIA) Impairment Scale. Clin Orthop Relat Res. 2017 May;475(5):1499-504.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Luan Gabriel Affonso, João Vitor Macedo de Oliveira, Maria Victória da Costa Farfan, Ana Clara Pinheiro Andrade, Juliana Silveira Sola, Mariana Alfena Ostwald, Milla Daudt Ribeiro, Gustavo Alves Henderson Cardoso, Maria Antônia Coelho Moreira, Fábio Lopes Telles

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os autores são detentores dos direitos autorais mediante uma licença CCBY 4.0.



